



Corporate Press Release

19th March 2012

Norgine Partners with Medical Futures for NORMACOL[®] in Canada

Norgine BV, the leading European specialty pharmaceutical company, has today announced that it has appointed Medical Futures as its partner for NORMACOL[®] in Canada. NORMACOL[®] is used for the gentle relief of occasional constipation. This agreement further cements the very successful working partnership between the two companies as Medical Futures already market MOVIPREP[®] in Canada.

Commenting on the agreement, Paul Pay VP of Corporate and Business Development commented: "We are delighted to extend our relationship with Medical Futures and we are sure this will expand the existing NORMACOL[®] business in Canada"

Colin Campbell, CEO of Medical Futures added that "This is a strategically important product for us and we are very happy to be able to provide Canadians with this proven remedy for constipation. We are also very pleased to have developed a strong business relationship with Norgine BV and look forward to building on our success with MOVIPREP[®] and creating a leading market position in gastroenterology remedies."

ENDS

About Norgine BV

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2011, Norgine's net product sales were €250 million and the company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology,

hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g. MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a bowel cleansing preparation, KLEAN-PREP[®] for large bowel preparation prior to colonoscopy or surgery, XIFAXAN[®] for the treatment of traveller's diarrhoea and ORAMORPH[®] for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France. For more information: www.norgine.com

Norgine Contact:

Julie Hornby-Winfield

Global Corporate Communications Manager

Tel: +44 1895 826600 or email to jhornbywinfield@norgine.com

About Medical Futures

Medical Futures, Inc. is a niche pharmaceutical company that has a focus on Gastroenterology, Pain Management, and Women's Health. The Company provides Canadians with safe, effective, and affordable products to help improve the overall quality of their lives. Current product offerings include: MOVIPREP[®], NORMACOL[®], DURELA[®], PEGALAX[™], FLORASTOR[®], PROFERRIN[®], IBEROGAST[®], PURFEM[™], and MUTAFLOR[®]. For more information: www.medfutures.com

Medical Futures contact:

Colin Campbell

CEO

Tel: 905-731-0294 or email to c.campbell@medfutures.com